Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other diug products that may have been associated with the specific failure or discrepancy.
Inspection Record
Lupin Limited — FDA 483 Findings
Inspectors Yvins DezanThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Equipment for adequate control over air pressure, humidity, temperature is not provided when appropriate for the manufacture, processing, packing or holding ofa diug product.
(Repeat) Written records of investigation of a dtug complaint do not include the findings of the investigation and the follow-up.
(Repeat) There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been ah-eady distributed.
The responsibilities and procedures applicable to the quality control unit are not [in writing] [fully followed].
Laborato1y controls do not include the establishment ofscientifically sound and appropriate specifications, test procedures designed to assure that components, drug products confo1m to appropriate standards of identity, strength, quality and purity.
Procedures designed to prevent microbiological contamination of dm g products purporting to be sterile are not established, written, or followed.
Substances required for equipment operations such as lubricants and coolants come in contact with diu g product containers, closures, dmg product so as to alter the safety, identity, strength, quality, or purity of the dmg product beyond the official or other established requirements.
(Repeat) Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
(Repeat) Employees engaged in the manufacture, processing, packing and holding of a drng product lack the training required to perfo1m their assigned functions.
About this record
Extracted automatically from the document US FDA published on 2023-04-14. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
